Is CJC-1295 Legal in Australia? (2026 Research Status)
Imagine you’re a researcher at an Australian university, designing a study on growth hormone-releasing hormone (GHRH) analogs. You’ve identified CJC-1295 as a compound of interest based on its unique pharmacokinetic profile. Before you can proceed, you need to answer a critical question: is this peptide legal to import, possess, and study in Australia?
The answer, as with many regulatory questions in peptide research, is more nuanced than a simple yes or no. Australia’s therapeutic goods framework treats different peptides in different ways, and the rules governing research use don’t always align with what you might read in online forums or community discussions.
In this guide, we’ll separate four common misconceptions about CJC-1295’s legal status in Australia from the regulatory reality — and point you toward the resources you need to navigate this landscape responsibly.
What Is CJC-1295?
Before diving into legality, a brief primer may be helpful. CJC-1295 is a synthetic analog of growth hormone-releasing hormone. It was designed to stimulate the pituitary gland to release growth hormone (GH) with a longer duration of action than native GHRH. Early-phase clinical research explored its pharmacokinetics and effects on GH and insulin-like growth factor 1 (IGF-1) secretion in human subjects Teichman et al., 2006.
There are two versions often discussed in research literature: CJC-1295 with Drug Affinity Complex (DAC) and CJC-1295 without DAC (sometimes called Mod GRF 1-29). The DAC modification significantly extends the peptide’s half-life by enabling it to bind to circulating albumin, a property first characterized in preclinical work by Jetté et al., 2005. This distinction has implications for both its research applications and its regulatory classification.
For a deeper dive into the compound’s mechanism and research history, see our full CJC-1295 compound profile.
Myth #1: “CJC-1295 Is Completely Banned in Australia”
The misconception: Many researchers assume that because CJC-1295 isn’t available over the counter or through standard pharmaceutical channels, it must be outright prohibited.
The reality: Australia regulates therapeutic goods through the Therapeutic Goods Administration (TGA), which classifies substances into schedules under the Poisons Standard. CJC-1295 is not listed as a registered medicine on the Australian Register of Therapeutic Goods (ARTG). This means it cannot be legally marketed or sold as a therapeutic product for human use within Australia.
However, “not registered” is not the same as “banned.” Australian law provides pathways for the legitimate use of unregistered substances in research contexts. Universities and licensed research institutions can often access such compounds through appropriate channels, subject to institutional ethics approvals and import permits.
The distinction matters: a substance’s regulatory status depends heavily on the context of its use — whether it’s being marketed as a medicine, used in a clinical trial, or employed in preclinical laboratory research. Researchers should verify the current scheduling status directly with the TGA, as classifications can change over time.
Myth #2: “All Peptides Face the Same Legal Treatment in Australia”
The misconception: Because peptides share a common biochemical category, people often assume they all face identical regulatory treatment.
The reality: Australian regulators evaluate each substance individually. Some peptides are classified as Prescription Only (Schedule 4), while others may fall under different schedules or remain unscheduled entirely. The classification depends on factors including the substance’s pharmacological activity, its history of clinical use, and its potential for misuse.
CJC-1295’s specific regulatory position is
